2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3944 A functional iPSC-derived 3D mini-bone model reveals native-like interactions between multiple myeloma cells and the bone microenvironment

Ann-Sophie Hainold, Christina Mathilde Verbruggen, PhD2, Seungbin Han3, Umair Munawar, PhD4, Silvia Nerreter5, Shilpa Kurian6, Cornelia Vogt7, Emma Besant8, Sven Neubert9, Yoko Tamamushi, MD10, Michael Hudecek, MD11, Leo Rasche Jr, MD12, Thomas Nerreter13, Markus Sauer14, Hermann Einsele, MD, PhD15, Johannes Waldschmidt, MD16, K. Martin Kortüm, MD17
1 University Hospital Würzburg, Würzburg, Bavaria, Germany
2 University Hospital Würzburg, Würzburg, Bavaria, Germany
3 University Hospital Würzburg, Würzburg, Bavaria, Germany
4 University Hospital Würzburg, Würzburg, Bavaria, Germany
5 University Hospital Würzburg, Würzburg, Bavaria, Germany
6 University Hospital Würzburg, Würzburg, Bavaria, Germany
7 University Hospital Würzburg, Würzburg, Bavaria, Germany
8 University Hospital Würzburg, Würzburg, Bavaria, Germany
9 University Hospital Würzburg, Würzburg, Bavaria, Germany
10 University Hospital Würzburg, Würzburg, Bavaria, Germany
11 University Hospital Würzburg, Würzburg, Bavaria, Germany
12 University Hospital Würzburg, Würzburg, Bavaria, Germany
13 University Hospital Würzburg, Würzburg, Bavaria, Germany
14 Julius-Maximilians-University Würzburg, Würzburg, Germany
15 University Hospital Würzburg, Würzburg, Bavaria, Germany
16 University Hospital Würzburg, Würzburg, Bavaria, Germany
17 University Hospital Würzburg, Würzburg, Bavaria, Germany

Introduction

The limited survival of patient-derived multiple myeloma (MM) cells ex vivo remains a major challenge for disease modelling and drug testing. Here, we present an induced pluripotent stem cell (iPSC)-derived three-dimensional bone organoid designed to recapitulate key features of the human bone marrow microenvironment and support the investigation of MM–microenvironment interactions.

Methods

We generated the organoid using three-dimensional tissue engineering exclusively from iPSCs, enabling the formation of a complex, mature human bone organoid within 14 days of culture. We characterized organoid development and maturation by qRT-PCR, immunohistochemistry (IHC), and confocal imaging, assessing pluripotency (OCT4+) and lineage commitment (brachyury (TBXT)+) during differentiation. In mature organoids, we analyzed vascular (CD31+), immune-like (CD45+), and osteogenic populations representing early (RUNX2+) and mature (osteopontin (OPN)+) stages. We co-cultured GFP-labeled MM cell lines (MM.1S and RPMI-8226) with the organoids to monitor tumor cell localization and interaction with the microenvironment. We quantified cytokine production (IL-6, TNF-α, and IFN-γ) before and during co-culture by ELISA. In addition, we co-cultured patient-derived primary MM cells with the organoids and assessed cell viability and proliferation.

Results

In the initial stages of organoid development, we assessed iPSC pluripotency by OCT4 immunostaining, providing the basis for differentiation into multiple cell lineages. The use of iPSCs as a single starting cell source enabled the generation of a complex organoid containing cell populations representing mesodermal, ectodermal, and endodermal lineages, with the aim of mimicking key aspects of the human bone marrow niche. Following mesodermal induction, expression of the progenitor marker TBXT was detected. During vascular induction, the developing organoids exhibited CD31-positive vascular structures, while subsequent osteogenic induction resulted in the appearance of RUNX2-positive osteogenic progenitors followed by OPN-expressing mature osteogenic cells.

Overall, these findings suggest that the organoids recapitulate several essential features of the human bone marrow microenvironment, including vascular, immune-like, and osteogenic components. Co-culture with MM cells was associated with changes in the cytokine secretion profile, indicating active interactions between tumor cells and the developing niche. While both MM cell lines and patient-derived primary MM cells remained viable during long-term co-culture, the organoids showed progressive structural changes that may reflect disease-associated remodeling of the microenvironment. In contrast, MM cells failed to survive or expand in the presence of non-viable organoids, supporting the importance of an intact microenvironment for MM cell maintenance. Ongoing work focuses on further characterization of the cellular composition and functionality of the organoids, quantitative validation of niche-specific features, and optimization of long-term culture conditions. These efforts are expected to further establish the model as a platform for studying MM–microenvironment interactions and for future applications in drug testing and disease modelling.

Conclusion

We established a scalable, fully human iPSC-derived bone organoid that integrates both bone and bone marrow components in a single construct. The model includes vascular, immune-like, and osteogenic compartments without requiring an extracellular matrix scaffold and with minimal growth factor supplementation, providing a fast and cost-effective alternative to existing bone organoid systems. Its ability to maintain patient-derived MM cells demonstrates that this engineering strategy preserves essential microenvironmental functions. Together, these features provide a technically accessible and physiologically relevant platform for MM research.

Ann-Sophie Hainold: No relevant conflicts of interest to declare.